Supplementary Appendix. 0 5 10 15 20 25 30 01234567891011 Thrombotic Risk Scores % of Patients Risk Categories Low Risk (n=3491) Intermediate Risk (n=2806)

Slides:

Advertisements

Similar presentations

Prevalence (%) Prevalence of CAC by Degree of cPB No Carotid Plaque cPB Tertile 1 cPB Tertile 2 cPB Tertile 3 (n=1,316) (n=1,498) (n=1,497) (n=1,497) Supplementary.

Advertisements

Figure 6: Risks of outcomes in the primary (A) and secondary (B) prevention cohorts for men in various BMI groups compared to patients in the “normal BMI”

Embargoed Until 10:45 a.m. ET, Tuesday, Nov. 10, 2015

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Elective Intra-aortic Balloon Counterpulsation During.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.

Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Medical Therapy With Versus Without Revascularization.

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Nuisance Bleeding With Prolonged Dual Antiplatelet.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.

Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE

Glycated hemoglobin and long-term prognosis in patients with suspected stable angina pectoris without diabetes mellitus: A prospective cohort study Eirik.

Prevention of CVD in Diabetes

Copyright © 2006 American Medical Association. All rights reserved.

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Supplementary Table 1 Independent Predictors of 2-Year Mortality

12 Month Outcomes in Patients with Diabetes Mellitus Implanted with a Resolute Zotarolimus-eluting Stent: Initial Results from the RESOLUTE Global Clinical.

Copyright © 2007 American Medical Association. All rights reserved.

Stent Thrombosis Rates in Contemporary Clinical Practice: Insight from a Large Australian Multi-centre Registry BP Yan*, TJ Kiernan, SJ Duffy, DJ Clark,

Influence of Body Mass Index on Long-Term Survival After Cardiac Catheterization Barak Zafrir, MD, Ronen Jaffe, MD, Ronen Rubinshtein, MD, Basheer Karkabi,

on behalf of the RE-DUAL PCI Steering Committee and Investigators

Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.

Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.

Glenn N. Levine et al. JACC 2016;68:

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Masaya Koshizaka, MD, PhD, Renato D. Lopes, MD, PhD, MHS, L

Glenn N. Levine et al. JACC 2016;68:

Lipoprotein insulin resistance score and risk of incident diabetes during extended follow- up of 20 years: The Women's Health Study Paulo H.N. Harada,

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease Glenn N. Levine, MD, FACC, FAHA,

Management of antiplatelet therapy in patients with coronary stents undergoing noncardiac surgery: association with adverse events A. Rodriguez, N. Guilera,

Dileep Raman et al. JACEP 2017;3:

Duration of Dual Antiplatelet Therapy

A B Yeom Supplementary Fig.2

Shikhar Agarwal, MD, MPH, Aatish Garg, MD, Akhil Parashar, MD, Lars G

STENT THROMBISIS Insights on Outcomes and Impact of DUAL ANTIPLATELET THERAPY Permanent Discontinuation SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE.

Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies

Significance of Periprocedural Myocardial Infarctions in Percutaneous Coronary Interventions A New Look at an Old Topic Abhiram Prasad, MD, FRCP, FESC,

Molly E. Waring, PhD, Jane S

Nat. Rev. Cardiol. doi: /nrcardio

Hisato Takagi, MD, PhD, Hideaki Manabe, MD, Takuya Umemoto, MD, PhD

Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different.

Prevention of CVD in Diabetes

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care Marc Cohen, MD Mayo Clinic Proceedings

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

To bypass or stent? The changing rules of an advancing game

(A) Multivariable Cox regressions showing the association of higher CHA2DS2-Vasc scores (≥6) and (B) R2CHA2DS2-Vasc scores (≥7) with 1-year mortality (CABG,

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Lars E. Laugsand et al. BTS 2016;j.jacbts

Glenn N. Levine et al. JACC 2011;58:e44-e122

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

Procedural Characteristics

Volume 75, Issue 1, Pages (January 2009)

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Davide Capodanno et al. JCIN 2009;2:

Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;

Associations between type of MI and incident HF

Davide Capodanno et al. JCIN 2009;2:

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Risk of venous thromboembolism by ABO blood type, factor V Leiden R506Q and prothrombin G20210A mutations among individuals in the Copenhagen General.

Figure 7. Subgroup analysis according to the study design and support of CPB during CABG. The study design and support of CPB did not affect the results.

The Clinical Significance and Management Implications of Chronic Total Occlusion Associated With Surgical Coronary Artery Revascularization Lorenzo Azzalini,

Association of body mass index with all-cause mortality in diabetes and non-diabetes populations, by smoking status. Association of body mass index with.

Multivariable-adjusted HRs and 95% CIs for outcomes for waist circumference. Multivariable-adjusted HRs and 95% CIs for outcomes for waist circumference.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

--- 6-months’ therapy months’ therapy Supplementary Figure 1.

Presentation transcript:

Supplementary Appendix

Thrombotic Risk Scores % of Patients Risk Categories Low Risk (n=3491) Intermediate Risk (n=2806) High Risk (n=1833) Distribution of Thrombotic Risk Score in ADAPT DES Patients Supplementary Figure 1A

Bleeding Risk Scores % of Patients Risk Categories Low Risk (n=4394) Intermediate Risk (n=3276) High Risk (n=460) Distribution of Bleeding Risk Score in ADAPT DES Patients Supplementary Figure 1B

Log Rank p < Months since PCI Cumulative Incidence (%) Risk Categories Low Risk 1.11% (37) Intermediate Risk 3.00% (79) High Risk 8.49% (144) Rates of Coronary Thrombotic Events at 2 Years by Level of Thrombotic Risk Supplementary Figure 2A

Log Rank p < Months since PCI Risk Categories Low Risk 2.36% (96) Intermediate Risk 4.45% (135) High Risk 9.35% (39) Cumulative Incidence (%) Rates of Major Bleeding at 2 Years by Level of Bleeding Risk Supplementary Figure 2B

Supplementary Table Associations Between Clinical Parameters and Thrombotic and Bleeding Events After Inclusion of DAPT Cessation in Each Model Parameter Coronary Thrombotic Event HR (95% CI) Major Bleeding HR (95% CI) Age, per year increase1.07 ( ) BMI < 25, kg/m ( ) BMI > 35, kg/m ( ) Anemia2.59 ( ) Triple therapy on discharge1.84 ( ) Current smoking1.63 ( )1.89 ( ) CrCl < 60 ml/min2.02 ( ) Diabetes Mellitus Non-insulin requiring1.69 ( ) Insulin Requiring3.40 ( ) Acute Coronary Syndrome Troponin negative1.34 ( ) Troponin positive2.20 ( ) Prior PCI1.89 ( ) Prior CABG1.87 ( ) BMI- body mass index; PCI-percutaneous coronary intervention; CABG-coronary artery bypass graft; HR – hazard ratio; CI – confidence interval; DAPT – dual antiplatelet therapy. HR (95% CI) generated from multivariable Cox models that include DAPT cessation as a time- varying covariate